June 10, 2019 07:34 AM EDTUpdated June 11, 04:32 AM

'We kept at it': Jeffrey Bluestone plots late-stage comeback after teplizumab shown to delay type 1 diabetes

Amber Tong

Late-stage data presented at the American Diabetes Association annual meeting in 2010 pushed Eli Lilly to put a crimp on teplizumab as the pharma giant …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

'We kept at it': Jeffrey Bluestone plots late-stage comeback after teplizumab shown to delay type 1 diabetes

Amber Tong

Sign up to read this article for free.

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

'We kept at it': Jef­frey Blue­stone plots late-stage come­back af­ter teplizum­ab shown to de­lay type 1 di­a­betes

Amber Tong

Sign up to read this article for free.

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

FDA says Ozem­pic, We­govy short­age is over

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

'We kept at it': Jeffrey Bluestone plots late-stage comeback after teplizumab shown to delay type 1 diabetes

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence